Sanofi (NASDAQ:SNY) Shares Purchased by Brooklyn Investment Group

Brooklyn Investment Group grew its position in shares of Sanofi (NASDAQ:SNY) by 397.0% during the fourth quarter, Holdings Channel reports. The firm owned 1,635 shares of the company’s stock after acquiring an additional 1,306 shares during the quarter. Brooklyn Investment Group’s holdings in Sanofi were worth $79,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of SNY. Stablepoint Partners LLC grew its holdings in shares of Sanofi by 0.8% in the third quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock valued at $1,377,000 after purchasing an additional 189 shares in the last quarter. PDS Planning Inc increased its position in shares of Sanofi by 3.1% during the third quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock worth $383,000 after acquiring an additional 200 shares during the period. Eagle Ridge Investment Management increased its position in shares of Sanofi by 3.8% during the third quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company’s stock worth $321,000 after acquiring an additional 203 shares during the period. Financial Advocates Investment Management boosted its holdings in Sanofi by 3.4% in the third quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock valued at $365,000 after purchasing an additional 206 shares during the period. Finally, Angeles Investment Advisors LLC grew its stake in Sanofi by 1.9% during the 3rd quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock worth $653,000 after purchasing an additional 210 shares in the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Stock Performance

Shares of SNY stock opened at $50.74 on Monday. The company has a market cap of $128.77 billion, a P/E ratio of 25.89, a PEG ratio of 1.17 and a beta of 0.57. The firm has a fifty day moving average price of $48.46 and a 200 day moving average price of $52.11. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. During the same period in the prior year, the firm posted $2.55 EPS. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. Sell-side analysts predict that Sanofi will post 3.94 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.